Department Of Clinical Pharmacy 2
51. Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021
52. Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021
53. Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021
54. Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019 A Systematic Analysis for the Global Burden of Disease Study 2019
55. Global, regional, and national age-sex-specific burden of diarrhoeal diseases, their risk factors, and aetiologies, 1990–2021, for 204 countries and territories: a systematic analysis for the Global Burden of Disease Study 2021
56. Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021
57. Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021
58. Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021
59. Global, regional and national burden of dietary iron deficiency from 1990 to 2021: a Global Burden of Disease study
60. Global, regional and national burden of dietary iron deficiency from 1990 to 2021: a Global Burden of Disease study
61. Nutritional Sources and Anticancer Potential of Phenethyl Isothiocyanate: Molecular Mechanisms and Therapeutic Insights
62. CAMP: a modular metagenomics analysis system for integrated multistep data exploration
63. Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023
64. Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023
65. Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023
66. The burden of bacterial antimicrobial resistance in the WHO Eastern Mediterranean Region 1990–2021: a cross-country systematic analysis with forecasts to 2050
67. Tracking development assistance for health and for COVID-19: a review of development assistance, government, out-of-pocket, and other private spending on health for 204 countries and territories, 1990–2050
68. Tracking development assistance for health and for COVID-19: a review of development assistance, government, out-of-pocket, and other private spending on health for 204 countries and territories, 1990–2050
69. Rumex Species: Phytochemistry, Pharmacology and Nutritional Potential for Food and Health Applications
70. Global burden of chronic respiratory diseases and risk factors, 1990–2019: an update from the Global Burden of Disease Study 2019
71. Global burden of chronic respiratory diseases and risk factors, 1990–2019: an update from the Global Burden of Disease Study 2019
72. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
73. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
74. Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050
75. Updated aspects of alpha-Solanine as a potential anticancer agent: Mechanistic insights and future directions
76. Global, regional, and national prevalence of adult overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021
77. Global, regional, and national prevalence of adult overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021
78. Global, regional, and national prevalence of adult overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021
79. Evaluating the Efficacy of Immunomodulatory Therapies in Rheumatoid Arthritis: A Clinical Study
80. Global, regional, and national burden of asthma and atopic dermatitis, 1990–2021, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021
81. Global, regional, and national burden of asthma and atopic dermatitis, 1990–2021, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021
82. Global, regional, and national burden of chronic respiratory diseases and impact of the COVID-19 pandemic, 1990–2023: a Global Burden of Disease study
83. Global, regional, and national burden of chronic respiratory diseases and impact of the COVID-19 pandemic, 1990–2023: a Global Burden of Disease study
84. Prioritizing safe schools in Nigeria: A key to sustainable educational development [commentary]
85. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021
86. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021
87. Nutraceutical Profiling, Bioactive Composition, and Biological Applications of Lepidium sativum L.
88. Global estimates on the number of people blind or visually impaired by cataract: a meta-analysis from 2000 to 2020
89. Global estimates on the number of people blind or visually impaired by cataract: a meta-analysis from 2000 to 2020
90. Anticancer properties of bromelain: State-of-the-art and recent trends
91. Phytates as a natural source for health promotion: A critical evaluation of clinical trials
92. Medicinal and mechanistic overview of artemisinin in the treatment of human diseases
93. Honokiol and its analogues as anticancer compounds: Current mechanistic insights and structure-activity relationship
94. Honokiol and its analogues as anticancer compounds: Current mechanistic insights and structure-activity relationship
95. Pharmacological Properties of Bergapten: Mechanistic and Therapeutic Aspects
96. Impact of Olive Oil Constituents on C-reactive Protein: In silico Evidence
97. An updated pharmacological insight into calotropin as a potential therapeutic agent in cancer
98. Global, Regional, and National Burden of Nontraumatic Subarachnoid Hemorrhage The Global Burden of Disease Study 2021
99. Global, Regional, and National Burden of Nontraumatic Subarachnoid Hemorrhage The Global Burden of Disease Study 2021
100. Global, Regional, and National Burden of Nontraumatic Subarachnoid Hemorrhage The Global Burden of Disease Study 2021
1 2 3